- Postimmunotherapy treatments yield favorable survival benefit in women with heavily pretreated ovarian cancer, including those who did not derive benefit from immune checkpoint inhibitors.
- Taxane- and platinum-based therapies were the most common subsequent treatments.
Why this matters
- Findings suggest immunotherapy improves efficacy of subsequent chemotherapy.
- 79 patients with recurrent ovarian cancer (median age, 57 years) who received ≥1 subsequent treatment after immune checkpoint inhibitors.
- Funding: MSK Cancer Center.
- 84% of patients had platinum-resistant ovarian cancer.
- Median time from diagnosis to immune checkpoint inhibitor initiation was 39.7 months and median number of treatment lines was 4.
- 20% of patients derived benefit from checkpoint inhibitors.
- Most common subsequent treatments (any line) were taxane (53%), platinum-based therapy (47%), pegylated liposomal doxorubicin (30%), and gemcitabine (22%).
- 59% of patients received bevacizumab.
- Median follow-up was 18.3 months postimmune checkpoint inhibitors and median OS was 18.3 (95% CI, 11.8-22.7) months.
- OS was not significantly different in patients who derived benefit from immune checkpoint inhibitors vs those who did not (aHR, 0.55; P=.19).
- Retrospective design.